本文已被:浏览 716次 下载 310次
Received:December 29, 2021 Published Online:September 20, 2022
Received:December 29, 2021 Published Online:September 20, 2022
中文摘要: 妇科恶性肿瘤是全球妇女发病和死亡的重要原因。尽管疫苗预防、早期筛查、手术、放化疗等临床手段不断发展,妇科恶性肿瘤的治疗取得了很大进展。但在目前的医疗环境下,机制不明、耐药敏感性低、早期诊断困难等因素限制了乳腺癌、卵巢癌、宫颈癌等妇科恶性肿瘤的防治。因此,阐明妇科恶性肿瘤的发病机制和耐药机制,寻找有效的干预靶点和生物标志物对当前妇科恶性肿瘤的防治具有重要意义。铁死亡是由Dixon等于2012年首次发现并命名的,它是一种新的细胞程序性死亡模式,近年来不断有研究表明,铁死亡发生机制与妇科肿瘤的发生、发展和治疗密切相关。 因此,本文从铁死亡的发病机制入手,描述其在当前妇科恶性肿瘤的研究进展,希望能为未来研究提供参考。
Abstract:Gynecological malignant tumor is an important cause of morbidity and mortality among women worldwide. Despite the continuous development of clinical means such as vaccine prevention, early screening, surgery, radiotherapy and chemotherapy, great progress has been made in the treatment of gynecological malignant tumors. However, in the current medical environment, unknown mechanisms, low sensitivity to drug resistance, difficulties in early diagnosis and other factors limit the prevention and treatment of gynecological malignant tumors such as breast cancer, ovarian cancer, cervical cancer and so on. Therefore, it is of great significance to clarify the pathogenesis and drug resistance mechanism of gynecological malignant tumors and find effective intervention targets and biomarkers for the prevention and treatment of gynecological malignant tumors. Iron death was first discovered and named by Dixon in 2012. It is a new programmed cell death mode. In recent years, continuous studies have shown that the mechanism of iron death is closely related to the occurrence, development and treatment of gynecological tumors. Therefore, starting with the pathogenesis of iron death, this paper describes its current research progress in gynecological malignant tumors, hoping to provide reference for future research.
keywords: Ferroptosis Ovarian cancer Cervical cancer Breast cancer Drug resistance Iron homeostasis Lipid metabolism Antioxidant
文章编号: 中图分类号:R737 文献标志码:A
基金项目:
引用文本: